Latest Pharma Insights
Ex-MSD India Chief, PE Partnering For Bold New Pharma Play
Rehan Khan, a former managing director of MSD India and a global private equity firm are partnering to build a pharma platform, which they hope can disrupt the women's health and orthopedics segment.
Scrip - June 5, 2026
Rehan Khan, a former managing director of MSD India and a global private equity firm are partnering to build a pharma platform, which they hope can disrupt the women's health and orthopedics segment.
Scrip - June 5, 2026
EMA Not Reviewing OTC Nasal Decongestants After UK Cuts Duration Of Use
Exclusive: EMA confirms no safety review underway for xylometazoline or oxymetazoline nasal sprays following the UK's move to cap use at five days, leaving EU member states to decide independently whether to follow suit.
HBW Insight - June 5, 2026
Exclusive: EMA confirms no safety review underway for xylometazoline or oxymetazoline nasal sprays following the UK's move to cap use at five days, leaving EU member states to decide independently whether to follow suit.
HBW Insight - June 5, 2026
Dexcom Adds Dietitians And Coaching To CGM With Nutrisense Deal
Dexcom's deal for Nutrisense comes as glucose monitoring companies race to become full metabolic-health ecosystems — a contest the company is betting will be decided by coaching and nutrition support, not sensor accuracy alone.
Medtech Insight - June 5, 2026
Dexcom's deal for Nutrisense comes as glucose monitoring companies race to become full metabolic-health ecosystems — a contest the company is betting will be decided by coaching and nutrition support, not sensor accuracy alone.
Medtech Insight - June 5, 2026
Towa Profits Hit By Sunsho Write-Down Even As Sales Improve
Towa’s turnover growth almost met its forecasts in its full financial year – but profit was nearly wiped out by an impairment linked to its Sunsho business.
Generics Bulletin - June 5, 2026
Towa’s turnover growth almost met its forecasts in its full financial year – but profit was nearly wiped out by an impairment linked to its Sunsho business.
Generics Bulletin - June 5, 2026
Xbrane Gets October FDA Date For Refiled Lucentis Rival
Xbrane has revealed an FDA BsUFA date of October 29 for its long-in-development US biosimilar rival to Lucentis. The ranibizumab product is set to be marketed under the name Lucamzi, and if approved will face off against Byooviz, Cimerli and Nufymco.
Generics Bulletin - June 5, 2026
Xbrane has revealed an FDA BsUFA date of October 29 for its long-in-development US biosimilar rival to Lucentis. The ranibizumab product is set to be marketed under the name Lucamzi, and if approved will face off against Byooviz, Cimerli and Nufymco.
Generics Bulletin - June 5, 2026
Teva Joins EU Aflibercept Party
Teva has become the latest firm to enter Europe’s crowded aflibercept arena, rolling out Ahzantive pre-filled syringes across four major markets under its semi-exclusive tie-up with developer Formycon and Klinge Biopharma.
Generics Bulletin - June 5, 2026
Teva has become the latest firm to enter Europe’s crowded aflibercept arena, rolling out Ahzantive pre-filled syringes across four major markets under its semi-exclusive tie-up with developer Formycon and Klinge Biopharma.
Generics Bulletin - June 5, 2026
US Sunosi Settlement Removes Near-Term Generic Potential
Aurobindo’s patent-litigation settlement ends Sunosi ANDA litigation with Axsome, removing the last pending challenge and setting generic entry around 2040.
Generics Bulletin - June 5, 2026
Aurobindo’s patent-litigation settlement ends Sunosi ANDA litigation with Axsome, removing the last pending challenge and setting generic entry around 2040.
Generics Bulletin - June 5, 2026
Can The UK Medtech Market Go Toe-To-Toe With The US and EU?
Gerard Hanratty says that the UK can take a ‘flexible’ approach amid diverging US and EU rules on medtech and AI.
Medtech Insight - June 5, 2026
Gerard Hanratty says that the UK can take a ‘flexible’ approach amid diverging US and EU rules on medtech and AI.
Medtech Insight - June 5, 2026
Brain Cancer Research: Why Shilpa Medicare’s Gate2Brain Investment Matters
Shilpa Medicare’s investment in Barcelona-based biotech Gate2Brain is small but could change the game for lead candidate G2B-002, targeted at brain tumors that are among the most lethal pediatric cancers.
Scrip - June 5, 2026
Shilpa Medicare’s investment in Barcelona-based biotech Gate2Brain is small but could change the game for lead candidate G2B-002, targeted at brain tumors that are among the most lethal pediatric cancers.
Scrip - June 5, 2026
Lupeng’s Jaypirca Challenger Wins China Approval In 3L Mantle Cell Lymphoma
Lupeng’s rocbrutinib was conditionally approved for the third-line treatment of mantle cell lymphoma in China on June 4. The molecule is also currently being evaluated in a global head-to-head Phase III trial versus Jaypirca for second-line chronic lymphocytic leukemia/small lymphocytic lymphoma.
Scrip - June 5, 2026
Lupeng’s rocbrutinib was conditionally approved for the third-line treatment of mantle cell lymphoma in China on June 4. The molecule is also currently being evaluated in a global head-to-head Phase III trial versus Jaypirca for second-line chronic lymphocytic leukemia/small lymphocytic lymphoma.
Scrip - June 5, 2026
Chinese Oral, Injectable GLP-1s Show Variable Efficacy, Safety Ahead Of ADA
Chinese firms disclose Phase II data for two oral and one injectable GLP-1 receptor agonist in weight management before the American Diabetes Association meeting, with data from five more Phase II trials of China-originated drugs in obesity upcoming.
Scrip - June 5, 2026
Chinese firms disclose Phase II data for two oral and one injectable GLP-1 receptor agonist in weight management before the American Diabetes Association meeting, with data from five more Phase II trials of China-originated drugs in obesity upcoming.
Scrip - June 5, 2026
EULAR: Novartis Closes In On Final Approval For Cosentyx
The Swiss major has presented positive data on the big-selling IL-17A inhibitor showing sustained remission versus placebo in twice as many patients suffering from polymyalgia rheumatica.
Scrip - June 5, 2026
The Swiss major has presented positive data on the big-selling IL-17A inhibitor showing sustained remission versus placebo in twice as many patients suffering from polymyalgia rheumatica.
Scrip - June 5, 2026
From Fast Follower To Innovator: Korea Capturing Global Pharma Interest
KHIDI president Soon-Do Cha talks to Scrip about why South Korea’s significance as a global partner is rising, what’s driving recent platform deals, and the government agency’s breadth of support for Korean companies.
Scrip - June 5, 2026
KHIDI president Soon-Do Cha talks to Scrip about why South Korea’s significance as a global partner is rising, what’s driving recent platform deals, and the government agency’s breadth of support for Korean companies.
Scrip - June 5, 2026
ADA 2026: Implantables, Interoperability, And AI Signal A CGM Market In Transition
Next-gen algorithms, 3-year implantable sensors, and AI agents redefine diabetes tech. A look at key device innovations debuting in New Orleans.
Medtech Insight - June 5, 2026
Next-gen algorithms, 3-year implantable sensors, and AI agents redefine diabetes tech. A look at key device innovations debuting in New Orleans.
Medtech Insight - June 5, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest: NIH studies kratom for opioid addiction; Kentucky representative readies bill to help hemp industry; Mexico firm’s topical OTCs on import alert; final June deadline for OMUFA facility fees; C&D, P&G executives make investor rounds in Paris.
HBW Insight - June 5, 2026
Weekly digest: NIH studies kratom for opioid addiction; Kentucky representative readies bill to help hemp industry; Mexico firm’s topical OTCs on import alert; final June deadline for OMUFA facility fees; C&D, P&G executives make investor rounds in Paris.
HBW Insight - June 5, 2026
Ex-MSD India Chief, PE Partnering For Bold New Pharma Play
Rehan Khan, a former managing director of MSD India and a global private equity firm are partnering to build a pharma platform, which they hope can disrupt the women's health and orthopedics segment.
Scrip - June 5, 2026
Rehan Khan, a former managing director of MSD India and a global private equity firm are partnering to build a pharma platform, which they hope can disrupt the women's health and orthopedics segment.
Scrip - June 5, 2026
Brain Cancer Research: Why Shilpa Medicare’s Gate2Brain Investment Matters
Shilpa Medicare’s investment in Barcelona-based biotech Gate2Brain is small but could change the game for lead candidate G2B-002, targeted at brain tumors that are among the most lethal pediatric cancers.
Scrip - June 5, 2026
Shilpa Medicare’s investment in Barcelona-based biotech Gate2Brain is small but could change the game for lead candidate G2B-002, targeted at brain tumors that are among the most lethal pediatric cancers.
Scrip - June 5, 2026
Lupeng’s Jaypirca Challenger Wins China Approval In 3L Mantle Cell Lymphoma
Lupeng’s rocbrutinib was conditionally approved for the third-line treatment of mantle cell lymphoma in China on June 4. The molecule is also currently being evaluated in a global head-to-head Phase III trial versus Jaypirca for second-line chronic lymphocytic leukemia/small lymphocytic lymphoma.
Scrip - June 5, 2026
Lupeng’s rocbrutinib was conditionally approved for the third-line treatment of mantle cell lymphoma in China on June 4. The molecule is also currently being evaluated in a global head-to-head Phase III trial versus Jaypirca for second-line chronic lymphocytic leukemia/small lymphocytic lymphoma.
Scrip - June 5, 2026
Chinese Oral, Injectable GLP-1s Show Variable Efficacy, Safety Ahead Of ADA
Chinese firms disclose Phase II data for two oral and one injectable GLP-1 receptor agonist in weight management before the American Diabetes Association meeting, with data from five more Phase II trials of China-originated drugs in obesity upcoming.
Scrip - June 5, 2026
Chinese firms disclose Phase II data for two oral and one injectable GLP-1 receptor agonist in weight management before the American Diabetes Association meeting, with data from five more Phase II trials of China-originated drugs in obesity upcoming.
Scrip - June 5, 2026
EULAR: Novartis Closes In On Final Approval For Cosentyx
The Swiss major has presented positive data on the big-selling IL-17A inhibitor showing sustained remission versus placebo in twice as many patients suffering from polymyalgia rheumatica.
Scrip - June 5, 2026
The Swiss major has presented positive data on the big-selling IL-17A inhibitor showing sustained remission versus placebo in twice as many patients suffering from polymyalgia rheumatica.
Scrip - June 5, 2026
From Fast Follower To Innovator: Korea Capturing Global Pharma Interest
KHIDI president Soon-Do Cha talks to Scrip about why South Korea’s significance as a global partner is rising, what’s driving recent platform deals, and the government agency’s breadth of support for Korean companies.
Scrip - June 5, 2026
KHIDI president Soon-Do Cha talks to Scrip about why South Korea’s significance as a global partner is rising, what’s driving recent platform deals, and the government agency’s breadth of support for Korean companies.
Scrip - June 5, 2026
Dexcom Adds Dietitians And Coaching To CGM With Nutrisense Deal
Dexcom's deal for Nutrisense comes as glucose monitoring companies race to become full metabolic-health ecosystems — a contest the company is betting will be decided by coaching and nutrition support, not sensor accuracy alone.
Medtech Insight - June 5, 2026
Dexcom's deal for Nutrisense comes as glucose monitoring companies race to become full metabolic-health ecosystems — a contest the company is betting will be decided by coaching and nutrition support, not sensor accuracy alone.
Medtech Insight - June 5, 2026
Can The UK Medtech Market Go Toe-To-Toe With The US and EU?
Gerard Hanratty says that the UK can take a ‘flexible’ approach amid diverging US and EU rules on medtech and AI.
Medtech Insight - June 5, 2026
Gerard Hanratty says that the UK can take a ‘flexible’ approach amid diverging US and EU rules on medtech and AI.
Medtech Insight - June 5, 2026
ADA 2026: Implantables, Interoperability, And AI Signal A CGM Market In Transition
Next-gen algorithms, 3-year implantable sensors, and AI agents redefine diabetes tech. A look at key device innovations debuting in New Orleans.
Medtech Insight - June 5, 2026
Next-gen algorithms, 3-year implantable sensors, and AI agents redefine diabetes tech. A look at key device innovations debuting in New Orleans.
Medtech Insight - June 5, 2026
EMA Not Reviewing OTC Nasal Decongestants After UK Cuts Duration Of Use
Exclusive: EMA confirms no safety review underway for xylometazoline or oxymetazoline nasal sprays following the UK's move to cap use at five days, leaving EU member states to decide independently whether to follow suit.
HBW Insight - June 5, 2026
Exclusive: EMA confirms no safety review underway for xylometazoline or oxymetazoline nasal sprays following the UK's move to cap use at five days, leaving EU member states to decide independently whether to follow suit.
HBW Insight - June 5, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest: NIH studies kratom for opioid addiction; Kentucky representative readies bill to help hemp industry; Mexico firm’s topical OTCs on import alert; final June deadline for OMUFA facility fees; C&D, P&G executives make investor rounds in Paris.
HBW Insight - June 5, 2026
Weekly digest: NIH studies kratom for opioid addiction; Kentucky representative readies bill to help hemp industry; Mexico firm’s topical OTCs on import alert; final June deadline for OMUFA facility fees; C&D, P&G executives make investor rounds in Paris.
HBW Insight - June 5, 2026
Towa Profits Hit By Sunsho Write-Down Even As Sales Improve
Towa’s turnover growth almost met its forecasts in its full financial year – but profit was nearly wiped out by an impairment linked to its Sunsho business.
Generics Bulletin - June 5, 2026
Towa’s turnover growth almost met its forecasts in its full financial year – but profit was nearly wiped out by an impairment linked to its Sunsho business.
Generics Bulletin - June 5, 2026
Xbrane Gets October FDA Date For Refiled Lucentis Rival
Xbrane has revealed an FDA BsUFA date of October 29 for its long-in-development US biosimilar rival to Lucentis. The ranibizumab product is set to be marketed under the name Lucamzi, and if approved will face off against Byooviz, Cimerli and Nufymco.
Generics Bulletin - June 5, 2026
Xbrane has revealed an FDA BsUFA date of October 29 for its long-in-development US biosimilar rival to Lucentis. The ranibizumab product is set to be marketed under the name Lucamzi, and if approved will face off against Byooviz, Cimerli and Nufymco.
Generics Bulletin - June 5, 2026
Teva Joins EU Aflibercept Party
Teva has become the latest firm to enter Europe’s crowded aflibercept arena, rolling out Ahzantive pre-filled syringes across four major markets under its semi-exclusive tie-up with developer Formycon and Klinge Biopharma.
Generics Bulletin - June 5, 2026
Teva has become the latest firm to enter Europe’s crowded aflibercept arena, rolling out Ahzantive pre-filled syringes across four major markets under its semi-exclusive tie-up with developer Formycon and Klinge Biopharma.
Generics Bulletin - June 5, 2026
US Sunosi Settlement Removes Near-Term Generic Potential
Aurobindo’s patent-litigation settlement ends Sunosi ANDA litigation with Axsome, removing the last pending challenge and setting generic entry around 2040.
Generics Bulletin - June 5, 2026
Aurobindo’s patent-litigation settlement ends Sunosi ANDA litigation with Axsome, removing the last pending challenge and setting generic entry around 2040.
Generics Bulletin - June 5, 2026
ASCO 2026: Standout Wins And Strategic Shifts
Revolution Medicines' PDAC survival data headlined the recent ASCO meeting, alongside practice-changing readouts from J&J and Lilly, a crowded ADC and bispecific field, and Chinese biotechs delivering increasingly competitive results.
In Vivo - June 4, 2026
Revolution Medicines' PDAC survival data headlined the recent ASCO meeting, alongside practice-changing readouts from J&J and Lilly, a crowded ADC and bispecific field, and Chinese biotechs delivering increasingly competitive results.
In Vivo - June 4, 2026
The CEO Who Wants to Make Tacrolimus History
Eledon CEO David-Alexandre Gros is advancing tegoprubart, a CD40L blocker showing dramatically fewer side effects than tacrolimus, toward Phase III kidney transplant trials and beyond.
In Vivo - June 4, 2026
Eledon CEO David-Alexandre Gros is advancing tegoprubart, a CD40L blocker showing dramatically fewer side effects than tacrolimus, toward Phase III kidney transplant trials and beyond.
In Vivo - June 4, 2026